Literature DB >> 32908828

Eribulin and Confusion: A Previously Unknown Drug Side-Effect.

Abu Baker Sheikh1, Abhilash Perisetti2, Nismat Javed3, Rahul Shekhar1.   

Abstract

Eribulin is an antineoplastic agent used in advanced breast cancer refractory to anthracycline and taxane treatment regimens. A wide variety of side effects with unclear mechanisms have been noted, but encephalopathy has not been widely reported. Here we describe the case of a middle-aged woman treated with eribulin for advanced breast cancer who subsequently developed central nervous system drug-induced toxicity but improved promptly with steroid administration. LEARNING POINTS: Eribulin-induced encephalopathy is a diagnosis of exclusion and should be included in the differential diagnosis of patients treated with eribulin and presenting with altered mental status.Eribulin can cross the blood-brain barrier.Steroids and drug cessation should be the mainstay of treatment in cases of eribulin-induced encephalopathy. © EFIM 2020.

Entities:  

Keywords:  Eribulin; breast cancer; encephalopathy

Year:  2020        PMID: 32908828      PMCID: PMC7473676          DOI: 10.12890/2020_001708

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  5 in total

1.  Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.

Authors:  Shigeto Maeda; Michiyo Saimura; Shigeki Minami; Kaname Kurashita; Reiki Nishimura; Yuichiro Kai; Hiroshi Yano; Kohjiro Mashino; Shoshu Mitsuyama; Mototsugu Shimokawa; Kazuo Tamura
Journal:  Breast       Date:  2017-01-03       Impact factor: 4.380

2.  Novel second generation analogs of eribulin. Part III: Blood-brain barrier permeability and in vivo activity in a brain tumor model.

Authors:  Sridhar Narayan; Eric M Carlson; Hongsheng Cheng; Krista Condon; Hong Du; Sean Eckley; Yongbo Hu; Yimin Jiang; Vipul Kumar; Bryan M Lewis; Philip Saxton; Edgar Schuck; Boris M Seletsky; Karen Tendyke; Huiming Zhang; Wanjun Zheng; Bruce A Littlefield; Murray J Towle; Melvin J Yu
Journal:  Bioorg Med Chem Lett       Date:  2011-01-26       Impact factor: 2.823

3.  Safety of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer: a single-center experience.

Authors:  Icro Meattini; Isacco Desideri; Vanessa Di Cataldo; Giulio Francolini; Carla De Luca Cardillo; Vieri Scotti; Mauro Loi; Beatrice Detti; Monica Mangoni; Benedetta Agresti; Valentina Baldazzi; Daniela Greto; Donato Casella; Marco Bernini; Luis Jose Sanchez; Lorenzo Orzalesi; Jacopo Nori; Massimiliano Fambrini; Simonetta Bianchi; Lorenzo Livi
Journal:  Future Oncol       Date:  2016-03-09       Impact factor: 3.404

4.  Activity of Eribulin Mesylate in Brain Metastasis from Breast Cancer: A Stone in a Pond?

Authors:  Giovanna Catania; Paola Malaguti; Simona Gasparro; Francesco Cognetti; Antonello Vidiri; Alessandra Fabi
Journal:  Oncology       Date:  2018-07-24       Impact factor: 2.935

5.  Real-world efficacy and safety of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer center.

Authors:  Milana Bergamino Sirvén; Adela Fernández-Ortega; Agostina Stradella; Idoia Morilla; Catalina Falo; Silvia Vázquez; Roser Castany; Rafael Villanueva; Sabela Recalde; Valentí Navarro Pérez; Miguel Gil-Gil; Sonia Pernas
Journal:  BMC Pharmacol Toxicol       Date:  2019-11-21       Impact factor: 2.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.